PlexusDx compounded semaglutide is prepared by licensed 503A pharmacies and dosed under physician supervision, ensuring safety at any level
Trusted research-grade multi-agonist peptide in an ergonomic pen device
GLP-1 Receptor Agonist Intolerance: When It May Be Time to Consider Endoscopic Sleeve Author By: Dr
This article was previously distributed in the August 22, 2023, educational email of the Patient Safety Authority, available at About the Author Patient Safety Authority (patientsafety.pa.gov) is an independent state agency that oversees the Pennsylvania Patient Safety Reporting System (PA-PSRS), the largest database of its kind in the United States.
Estimates from a meta-analysis suggest that the global prevalence of nonalcoholic fatty liver disease (NAFLD) is 30.1%, with a significant increase from 25.3% (19902006) to 38.2% (20162019) over the last three decades
Reports indicate that the incidence correlates with higher dosing, and onset occurs within the first month of therapy and upon dose escalation
